Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-Label Phase 2 Trial of Aztreonam for Inhalation in Pediatric Cystic Fibrosis Patients with New Pseudomonas aeruginosa Infection
2011-001255-36Phase 2Completed
- Sponsor
- Gilead Sciences
- Start
- Oct 2011
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of aztreonam in cystic fibrosis (CF) and Pseudomonal infection, sponsored by Gilead Sciences. Primary endpoints: Proportion of subjects with sustained Pseudomonas aeruginosa-negative cultures through Day 196 and Microbiological culture status at each time point. Started Oct 2011; status: completed.
02
Drugs
aztreonam
03
Conditions
cystic fibrosis (CF)Pseudomonal infection
Beyond the preview
Go deeper on 2011-001255-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001255-36.